<SEC-DOCUMENT>0001683168-19-003033.txt : 20190924
<SEC-HEADER>0001683168-19-003033.hdr.sgml : 20190924
<ACCEPTANCE-DATETIME>20190924105934
ACCESSION NUMBER:		0001683168-19-003033
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190924
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190924
DATE AS OF CHANGE:		20190924

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37487
		FILM NUMBER:		191109610

	BUSINESS ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aethlon_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<B>September 24, 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aethlon Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>001-37487</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13-3632859</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer Identification No.)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of incorporation)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>9635 Granite Ridge Drive, Suite 100</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>San Diego, California</B></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>92123</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code: 858-459-7800 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Not applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<U>see</U> General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9744;</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 96%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9744;</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9744;</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9744;</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section
12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 31%; border: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="width: 19%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol</FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AEMD</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Nasdaq Capital Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 8.01</B></TD><TD><B>Other Events.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
September 24, 2019, the Company issued a press release announcing its collaboration to identify exosomes involved in cancer progression
and treatment resistance. The collaborator also announced the collaboration through its own press release. Copies of those press
releases are attached as Exhibit 99.1 hereto and are incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 9.01</B></TD><TD><B>Financial Statements and Exhibits</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibit No.</U></FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Description</U></FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="aethlon_8k-ex9901.htm">Press Releases dated September 24, 2019.</A></FONT></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aethlon Medical, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: September 24, 2019</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 51%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ James B. Frakes</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">James B. Frakes</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>aethlon_8k-ex9901.htm
<DESCRIPTION>PRESS RELEASES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="logo.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aethlon Announces Collaboration to Identify
Exosomes Involved in Cancer Progression and Treatment Resistance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Exosome based liquid biopsies have
potential to transform cancer diagnostics and treatments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SAN DIEGO (September 24, 2019) &ndash;
EXOSOME SCIENCES, a subsidiary of Aethlon Medical, Inc. (<B>Nasdaq: AEMD</B>), announced a research collaboration to identify and
characterize exosomes derived from patients with solid tumors such as pancreas cancer, as well as from families with genetically
high risk of developing cancer. These cancer-derived exosomes may serve as early markers for cancer diagnostics, cancer progression
and treatment resistance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For more information about this partnership please visit: https://www.hoag.org/news/hoag-to-study-unique-early-disease-markers/</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ABOUT EXOSOME SCIENCES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exosome Sciences, Inc., a majority owned subsidiary of Aethlon
Medical, Inc., is a diagnostic company focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological
disease progression. Aethlon Medical, Inc. is a therapeutic company focused on addressing unmet needs in cancer and infectious
diseases. The Aethlon Hemopurifier&reg; is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening
viral infections. In cancer, the Hemopurifier&reg; depletes the presence of circulating tumor-derived exosomes that promote immune
suppression, seed the spread of metastasis and inhibit the benefit of leading cancer therapies. The Hemopurifier&reg; is an FDA
designated &quot;Breakthrough Device&quot; related to the treatment of individuals with advanced or metastatic cancer who are either
unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate
in the development or severity of the disease cancer. The Hemopurifier also holds a Breakthrough Device designation related to
life-threatening viruses that are not addressed with approved therapies. Additional information can be found online at www.AethlonMedical.com
and www.ExosomeSciences.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, that involve risks and uncertainties. Statements containing words such as &quot;may,&quot; &quot;believe,&quot; &quot;anticipate,&quot;
&quot;expect,&quot; &quot;intend,&quot; &quot;plan,&quot; &quot;project,&quot; &quot;will,&quot; &quot;projections,&quot; &quot;estimate,&quot;
or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks
and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors
that may contribute to such differences include, without limitation, the Company's ability to raise additional funds and maintain
its listing on the Nasdaq Capital Market, or any other national securities exchange, the risk that the Company&rsquo;s collaborations
with hospitals will not be successful, that the Company&rsquo;s subsidiary will not be able to commercialize its products, that
the FDA will not approve the initiation or continuation of the Company's clinical programs or provide market clearance of the Company's
products, the Company's ability to complete the development of the Hemopurifier and other planned products, the Company's ability
to manufacture its products either internally or through outside companies, the impact of government regulations, patent protection
on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological
change, and other risk factors. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional
factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the
caption &quot;Risk Factors&quot; in the Company's Annual Report on Form 10-K for the year ended March 31, 2019, and in the Company's
other filings with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q. Except as may be required
by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jim Frakes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">858-459-7800 x3300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jfrakes@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David Schull or Maggie Beller</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Russo Partners, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David.Schull@RussoPartnersLLC.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Maggie.Beller@RussoPartnersLLC.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">212-845-4271</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NEWPORT BEACH, CALIF., September 24, 2019 &ndash; </B>Hoag
Memorial Hospital Presbyterian announced today the start of a research study to identify and characterize potential early
disease markers for cancer diagnostics, cancer progression and treatment resistance.</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)">In
partnership with Exosome Sciences, a subsidiary of Aethlon Medical, Inc. (Nasdaq: AEMD), scientists will study exosomes in
cancer patients and individuals at high genetic risk for cancer. Exosomes are nanoparticles that are abundantly released from
cancer cells and provide a snapshot of a tumor&rsquo;s genetic and protein cargo, making them important targets for
non-invasive liquid biopsies in cancer.</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)">&ldquo;Liquid
biopsies have the potential to facilitate the early detection of cancer and the assessment of the efficacy of potential
treatments in real time. This may prove to be a critical tool in our ongoing efforts to help patients with cancer,&rdquo;
said Michael Demeure, M.D., program director of Precision Medicine at Hoag&nbsp;and the principal investigator on the
study at Hoag. &ldquo;Hoag has an active&nbsp;Hereditary Cancer Program&nbsp;that supports a number of individuals and
families at high risk of developing cancer and is committed to achieving breakthroughs in the detection of cancer at its
earliest possible and most treatable stage.&rdquo;</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)">&ldquo;Liquid
biopsies are a rapidly developing field of non-invasive tests for patients with and at risk for cancer,&rdquo; said Timothy Rodell,
M.D., CEO of Exosome Sciences and Aethlon Medical, Inc. &ldquo;Our proprietary exosome diagnostics represent a potentially powerful
addition to the liquid biopsy field. This partnership with Hoag may significantly accelerate our development of exosome based liquid
biopsies and may provide deep insights into the detection, progression and treatment options for cancer patients and their families.
We are delighted to have the opportunity to work with Dr. Demeure and the Hoag team on this project.&rdquo;</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)">Hoag&rsquo;s
Hereditary Cancer Program and many aspects of its cancer research are supported by philanthropy.</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)">For
more information on the research studies and clinical trials at Hoag, visit&nbsp;https://www.hoag.org/specialties-services/other-programs-services/clinical-research/available-clinical-trials/.</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)"><B>ABOUT
HOAG MEMORIAL HOSPITAL PRESBYTERIAN</B></P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)">Hoag
is an approximately $1 billion nonprofit, regional health care delivery network in Orange County, California, that treats
more than 30,000 inpatients and 450,000 outpatients annually. Hoag consists of two acute-care hospitals &ndash; Hoag Hospital
Newport Beach, which opened in 1952, and Hoag Hospital Irvine, which opened in 2010 &ndash; in addition to eight health
centers and 11 urgent care centers. Hoag is a designated Magnet<SUP>&reg;</SUP> hospital by the American Nurses Credentialing
Center (ANCC). Hoag offers a comprehensive blend of health care services that includes five institutes providing specialized
services in the following areas: cancer, heart and vascular,&nbsp;neurosciences,&nbsp;women&rsquo;s health, and orthopedics
through Hoag&rsquo;s affiliate, Hoag Orthopedic Institute<U>, </U>which consists of an orthopedic hospital and two ambulatory
surgical centers. Hoag has been named one of the Best Regional Hospitals in the 2019 - 2020 <I>U.S. News &amp; World
Report</I>, and<I>Becker&rsquo;s Healthcare</I>&nbsp;named Hoag as one of the 2018 &ldquo;100 Great Hospitals in
America&rdquo; &ndash; a designation Hoag has received five times. For an unprecedented 23 years, residents of Orange County
have chosen Hoag as one of the county&rsquo;s best hospitals in a local newspaper survey. Visit&nbsp;www.hoag.org&nbsp;for
more information.</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0px; background-color: rgb(255, 255, 255)">#
# #</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0px; background-color: rgb(255, 255, 255)">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)">To
download the official press release, please click&nbsp;here.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" != . # 2(  A$! Q$!_\0
M'0 !  (# 0$! 0            8'! 4( 0,""?_$ $80  $#!  $ @8%!@L)
M      $" P0 !081!Q(A,1-!"")187&!%!4R0I$6(U*AL=$7)S,W57)S=).R
MP3A#5&2"DK/"X?_$ !H! 0 # 0$!               #! 4! @;_Q  F$0 "
M @$%  $#!0           0(#$002$R$Q02)14A0C0F&!_]H # ,!  (1 Q$
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MOHYXY/@A[*I]UN=Z>3S/RC((]<]3RCKTW0%WL/-/MAQAQ#C:NRD*!!^8JO\
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MMQG);DI2=Z==4"M7QU6AXEY(G&L8D2$J'TIT>$PGSYCY_*MG!QNV05Q%QVG
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MB?-1\R:_&-8];L<MZ8EL8#:/O*^\L^TFMN*S9SS],?"_"'>Z7HI2E1$@I2E
M*4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 IJE* \4D*3H@$>PU\#"BD[,9D
@G^S%9%*+H8/DTPTU_)-(1_52!7UI2@%*4H!2E* __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
